Empire City Laboratories is proud to help combat the novel COVID-19 virus. Our dedicated employees are working tirelessly 24 hours a day and seven days a week to provide the diagnostic needs of our customers and their patients. As this pandemic continues to develop, so does Empire City Laboratories. We now offer several testing options for COVID-19.
Empire City Laboratories is here to help. Our customers and their patients are our number one priority. We realize that as this pandemic continues to develop so do the number of questions around the virus.
How do I get
Reach out to your health care provider immediately if you have any reason to suspect that you have COVID-19. They can provide you with direction as to where you can get tested. Empire City Laboratories continue to work directly with health care providers to provide several testing options.
Experience symptoms (fever, cough, shortness of breath)
Have been in close contact with a person with COVID-19
Have recently traveled from an area with a widespread outbreak
What types of tests
Roche developed PCR test – A testing protocol to identify if you’ve contracted the SARS-CoV-2 coronavirus. This test works by identifying the virus’ DNA through a process called polymerase chain reaction (PCR). The PCR test looks for telltale markers distinct to this viral strain. The sample can be obtained through a nasal swab. Click here for Fact sheet for Patients
DiaSorin developed Serology Antibody test – Empire City Laboratories has a long and successful partnership with DiaSorin. We have been utilizing their Liaison technology for years. Empire City Laboratories can now offer a fully automated serology test to detect antibodies against Sars-CoV-2 patients. DiaSorin has received FDA emergency use authorization for this test. The new serological test is designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for its ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses. The product has been designed to respond to the need to identify people in the population who have already been infected with the virus, where diagnosis has not been performed with a swab and a molecular diagnostic test. DiaSorin's response to COVID-19 continues through research projects that have been developed at the Saluggia and Gerenzano Centers in Italy. In February and March, from the novel coronavirus outbreak, DiaSorin has promptly devised and developed a rapid and accurate molecular diagnostic test on our LIAISON MDX platform intended to detect all the currently known variants of the COVID-19. The test enables sample-to-answer results within less than 60 minutes compared to the 5-7 hours currently necessary to report patient results. On April 17, DiaSorin announced that it has CE Marked the new LIAISON® SARS-CoV-2 S1/S2 IgG serological test and that it has received, on April 25, Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration. The test will respond to the need to identify the presence of antibodies in people who have been infected with SARS-CoV-2 and will be available on the 5,000 LIAISON® XL platforms installed worldwide. With a throughput of 170 patient samples per hour, the LIAISON® XL platform will support an increase in testing capacity and the availability of diagnostic testing in order to mitigate the potential impact of this virus.